These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32876799)

  • 1. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
    Bussing D; K Shah D
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies.
    Naware S; Bussing D; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):493-508. PubMed ID: 37558929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics.
    Gadkar K; Pastuskovas CV; Le Couter JE; Elliott JM; Zhang J; Lee CV; Sanowar S; Fuh G; Kim HS; Lombana TN; Spiess C; Nakamura M; Hass P; Shatz W; Meng YG; Scheer JM
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5390-400. PubMed ID: 26275136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits.
    Alshaikh RA; Salah El Din RA; Zaki RGE; Waeber C; Ryan KB
    Mol Pharm; 2024 Jul; 21(7):3310-3320. PubMed ID: 38856116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
    Li Z; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
    Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
    Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in The Mouse Eye Following Intravitreal Administration.
    Bussing D; Li Y; Guo L; Verma A; Sullivan JM; Shah DK
    J Pharm Sci; 2023 Aug; 112(8):2276-2284. PubMed ID: 37062415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
    Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
    Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.
    Le Merdy M; Tan ML; Babiskin A; Zhao L
    AAPS J; 2020 Jan; 22(2):26. PubMed ID: 31907674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic models for systemic disposition of protein therapeutics in rabbits.
    Jairam RK; Franz M; Hanke N; Kuepfer L
    Front Pharmacol; 2024; 15():1427325. PubMed ID: 39263566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
    Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
    Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic Modeling and Clinical Extrapolation for Topical Application of Pilocarpine on Eyelids: A Comprehensive Study.
    Lin J; Bu F; Wu D; Jiang P; He Q; Yang D; Zhu X; Wang Y; Xiang X
    J Pharm Sci; 2024 Sep; 113(9):2861-2870. PubMed ID: 38857643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.